Back to search

Article

PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to neoadjuvant chemotherapy in ER+/HER2- breast cancer

2023-04-19

Abstract excerpt

<h4>Background: </h4> Endeavors in molecular characterization of breast cancer paved the way to endocrine therapies in ER+/HER2- breast cancer, increasing response rates. Despite that, taxane-based neoadjuvant chemotherapy is still a cornerstone for breast-conserving surgery and complete tumor resection in locally advanced cancers with high recurrence risk. Nonetheless, chemoresistance risk is high. Therefore, pre...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
abd17b08-41c8-5db1-b4b8-212e6f84c2c0
DOI
10.21203/rs.3.rs-2820986/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to neoadjuvant chemotherapy in ER+/HER2- breast cancerDOI 10.21203/rs.3.rs-2820986/v1
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancerSemantic proximity
Novel Gene Signatures Predictive of Patient Recurrence-free Survival in HR+HER2- Breast CancerSemantic proximity
Adjuvant Chemotherapy Guidance for pT1-3N0-1 Breast Cancer Patients with HR+, HER2- subtype: a study based on SEER databaseSemantic proximity
Deciphering the gene regulatory circuitry governing chemoresistance in Triple-Negative Breast CancerSemantic proximity
The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtypeSemantic proximity
Clinicopathological features and prognosis of HER2 low-expression breast cancer: a single-center retrospective studySemantic proximity
Comparison of the Mutation Profiles of Triple-Negative Breast Cancers and Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers at the T2N0-1M0 StageSemantic proximity
Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancerSemantic proximity
Molecular characterization of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour responseSemantic proximity
Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer PatientsSemantic proximity
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.Semantic proximity
A novel gene signature to predict response to neoadjuvant chemotherapy and endocrine treatment in estrogen receptor-positive breast cancer patientsSemantic proximity
Select a neighboring publication to make it the new centre.